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Despite remarkable advances in the genomic characterization of adult melanoma, the molecular pathogenesis of
pediatric melanoma remains largely unknown. We analyzed 15 conventional melanomas (CMs), 3 melanomas
arising in congenital nevi (CNMs), and 5 spitzoid melanomas (SMs), using various platforms, including whole
genome or exome sequencing, the molecular inversion probe assay, and/or targeted sequencing. CMs
demonstrated a high burden of somatic single-nucleotide variations (SNVs), with each case containing a TERT
promoter (TERT-p) mutation, 13/15 containing an activating BRAF V600 mutation, and480% of the identified SNVs
consistent with UV damage. In contrast, the three CNMs contained an activating NRASQ61 mutation and no TERT-
p mutations. SMs were characterized by chromosomal rearrangements resulting in activated kinase signaling in
40%, and an absence of TERT-p mutations, except for the one SM that succumbed to hematogenous metastasis.
We conclude that pediatric CM has a very similar UV-induced mutational spectrum to that found in the adult
counterpart, emphasizing the need to promote sun protection practices in early life and to improve access to
therapeutic agents being explored in adults in young patients. In contrast, the pathogenesis of CNM appears to be
distinct. TERT-p mutations may identify the rare subset of spitzoid melanocytic lesions prone to disseminate.
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INTRODUCTION
Melanoma in children and adolescents is rare (Howlader
et al., 2013), but its incidence continues to rise, particularly
in the age group of 15–19 years (Wong et al., 2013). Although
certain predisposing factors, such as xeroderma pigmentosum,
family history of melanoma, and the presence of a large/giant
congenital melanocytic nevus, may increase the risk of
developing melanoma in early life, most pediatric cases
are sporadic (Pappo, 2003). In addition, similar to the adult
counterpart, pediatric melanoma is more prevalent among
fair-skinned individuals with a propensity to sunburn
(Whiteman et al., 1997; Strouse et al., 2005).
Over the past decade, considerable progress has been made
in elucidating the molecular pathogenesis of adult melanoma.
It has been shown that B60% of adult melanoma carry an
oncogenic BRAF V600 and B20% carry an oncogenic NRAS
mutation (Davies et al., 2002; Lee et al., 2011). These
discoveries have been rapidly translated into the clinic, as
exemplified by promising results using targeted therapy
against BRAF (Flaherty et al., 2011).
The development of melanoma is believed to be the result
of sequential acquisition of multiple mutations that cooperate
to induce overt malignancy. The first event is the acquisition of
a driver mutation in the RAS/RAF/mitogen-activated protein
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kinase pathway that promotes melanocytic proliferation. The
oncogenic mutations in BRAF and NRAS or the kinase fusions,
however, are insufficient on their own for the development of
cancer, as evident by their presence in the nevi of acquired,
congenital, or spitzoid types (Pollock et al., 2003; Bauer et al.,
2007; Wiesner et al., 2014). Additional genetic events, such as
disruption of the RB/p16 tumor suppressor pathway, activation
of the phosphatidylinositol 3 kinase/AKT pathway, and reactiva-
tion of telomere maintenance mechanisms, are necessary for
malignant transformation (Gray-Schopfer et al., 2006; Soo et al.,
2011). The recently discovered UV-signature mutations in TP53,
RAC1, STK19, PPP6C, PREX2, or those in the core promoter of
TERT (telomerase reverse transcriptase) are consistent with this
model of melanoma tumorigenesis (Berger et al., 2012; Hodis
et al., 2012; Horn et al., 2013; Huang et al., 2013).
Although the genomic characterization of adult melanoma
has drawn much attention and has been therapeutically
exploited, the genomic landscape of pediatric melanoma has
not been investigated. Childhood and adolescent melanomas
comprise a heterogeneous group of melanocytic neoplasms, in
terms of their clinical and pathological characteristics
that can be divided into three categories (Barnhill, 2006).
The first type is pediatric conventional melanoma (CM) that
shares the histological and clinical features of melanoma
arising in intermittently sun-exposed skin in adults. CM is
exceedingly rare to occur before puberty; hence, the majority
of pediatric patients with CM are teenagers (Barnhill et al.,
1995; Scalzo et al., 1997). The second type arises in
association with a large/giant congenital melanocytic nevus.
The lifetime risk of malignant transformation in a giant
congenital melanocytic nevus is 5 to 10% that most often
occurs in the first decade of life (Bittencourt et al., 2000; Bett,
2005; Krengel et al., 2006). Finally, in the spectrum of spitzoid
melanocytic tumors, spitzoid melanoma (SM) and atypical
Spitz tumor are distinct histologic variants with a less
aggressive clinical course compared with conventional
melanoma and rare extranodal metastatic potential (Barnhill
et al., 1995; Berk et al., 2010).
To explore the genomic landscape of pediatric melanoma,
we studied a well-annotated cohort of 23 children and
adolescents with ‘‘de novo conventional melanoma’’ (CM,
n¼15), ‘‘melanoma arising in a congenital melanocytic
nevus’’ (CNM, n¼3), and ‘‘spitzoid melanoma’’ (SM, n¼5)
(Figure 1 and Supplementary Table S1 and Supplementary
Figure S1 online).
RESULTS
Whole genome sequencing (WGS) and/or whole exome
sequencing (WES) were performed in 20 melanomas and
paired nontumor germline samples in parallel from 18 patients
(Figure 1). Data were analyzed for single-nucleotide variations
(SNVs), small insertion/deletions (indels), structural variations
(SVs), including inter- and intra-chromosomal rearrangements,
and copy number variations (CNVs). RNA sequencing was
successfully carried out in seven melanomas from five
patients. The molecular inversion probe (MIP) assay to
profile CNVs was performed in 19 melanomas. Targeted gene
sequence for BRAF, NRAS, and TERT-p was analyzed in all 23
melanomas. Immunohistochemistry for ALK and fluorescence
in situ hybridization (FISH) assays for ROS1, NTRK1, RET, and
BRAF were applied to five SMs to explore the presence of
selected gene rearrangements. Figure 1 shows major findings
in the genomic analysis, including the prevalence of mutations
in cancer genes and commonly mutated genes. Supple-
mentary Table S7 online shows the tier 1 variants (SNVs and
indels) as detected by WGS/WES in each sample, and
Supplementary Tables S9 online shows genes affected by
gains and losses in a statistically significant number of
subjects. Two patients (SJMEL001003 and SJMEL001004) each
contributed two tumor samples (D1 and D2) for WGS.
Comparison of the SNVs between D1 and D2 showed a high
percentage (>90%) of overlapping mutations in both patients
(Supplementary Tables S6 online).
UV-induced mutational spectrum in pediatric CM
Across the 13 CMs analyzed by WGS/WES, the coding
mutation rates averaged 14.36 per megabase (range, 3.21 to
52.65) (Supplementary Tables S2 and S3 online), comparable
to the mutation rates in the adult counterpart (range, 5–55)
(Berger et al., 2012). The ratio of nonsynonymous to silent
mutations across the WGS samples ranged from 1.27 to 2.22
(median, 1.82) (Supplementary Table S2 online), consistent
with a high load of nonselected passenger mutations. Impor-
tantly, an analysis of the type of SNV revealed that 480% of
the somatic mutations in CM were cytidine to thymidine (C–
4T) or guanine to adenine (G–4A) transitions, and X90% of
the mutations occurred 30 to a pyrimidine base, consistent
with UV-induced DNA damage (Supplementary Figure S3
online) (Pfeifer et al., 2005; Daya-Grosjean and Sarasin, 2005;
Leiter and Garbe, 2008; Wei et al., 2011). In addition, all of
the WGS samples with a high prevalence of C–4T/G–4A
mutations contained high numbers of tandem dinucleotide
CC–4TT mutations, accounting for 470% of their total
dinucleotide mutations (Supplementary Table S2 online).
Moreover, when the proportion of C–4T/G–4A mutations
was compared in relationship with the strand type, the number
of C–4T/G–4A mutations was lower on the transcribed than
on the nontranscribed strand (Supplementary Figure S4
online). Taken together, these data show evidence of UV-
induced damage in the genomic DNA of pediatric CM. The
mutation rates of the 2 CNMs varied by one order of
magnitude (1.85 vs. 15.03), likely reflective of their different
cumulative sun exposure (Supplementary Table S2 online).
SVs in pediatric melanoma
The SVs (deletions, insertions, and translocations) detected by
WGS ranged from 11 to 89 events per sample (median, 38)
(Supplementary Table S4 online). The 3 CMs harbored a
higher number of SVs (33–89) compared with the 2 CNMs
(11–19) and exhibited localized clustering of structural rear-
rangements in the regions of CNV, reminiscent of chromo-
tripsis. For example, we found high clusters of SVs on
chromosomes 2, 8, and 10, including a large number of
translocations between chromosomes 2 and 8 and high
clusters of SVs disrupting CLASP1 (a gene involved in the
regulation of microtubule dynamics) in SJMEL001003, clusters
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Figure 1. The clinical and genomic data for 23 pediatric melanomas analyzed by whole genome, whole exome, and/or the molecular inversion probe assay. The
mutation rate plot displays the mutation rates in the coding regions for the three subtypes of pediatric melanoma. The gray horizontal line shows the median coding
mutation rate in cutaneous melanoma in adults. The mutation spectrum plot in pediatric melanoma demonstrates a high rate of cytidine to thymidine (C–4T) or
guanine to adenine (G–4A) transitions in each conventional melanoma sample. The red horizontal line depicts the median rate of transition mutations in
melanoma in adults (adapted from data in Hodis et al., 2012). The MC1R variants shown in red font are associated with complete loss of gene function; the variants
shown in black font are associated with partial loss of gene function. * SJMEL001020 denoted with an asterisk is an acral melanoma. CTX, translocation;
DEL, deletion; MIP, molecular inversion probe assay; SV, structural variation; WES, whole exome sequencing; WGS, whole genome sequencing.
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of SVs on chromosome 7 (between 135 and 149 Mb) in
SJMEL001002, and regional clustering of intrachromosomal
translocations in chromosomes 7 and 8 in SJMEL001004
(Figure 2). Such complex SVs were not present in CNM.
RNA sequencing with fresh tumor was performed in
a subset of CMs (five samples) and CNM (one sample).
The detected SVs in each case (Supplementary Table S8
online) matched with the WGS data. RNA sequencing using
formalin-fixed, paraffin-embedded (FFPE) material was
attempted in 3 SMs, of which only one (SJMEL001032) had
high base coverage for data analysis, showing an in-frame
GSN/NTRK1 fusion (Supplementary Figure S13 online) that
was confirmed by the break-apart NTRK1 FISH assay
(Supplementary Figure S5 online). This finding is consistent
with the recent observations that identified chromosomal
rearrangement-induced fusions involving ROS1, NTRK1,
ALK, BRAF, and RET as a common mechanism of oncogene
activation in spitzoid neoplasms (Wiesner et al., 2014). A
panel of break-apart FISH assays for ROS1, NTRK1, BRAF, and
RET, applied to the four other SMs, identified an additional SM
(SJMEL001033) with BRAF rearrangement, whereas the three
other SMs were negative for gene rearrangements (Figure 1
and Supplementary Figure S5 online). None of the cases
expressed ALK protein by immunohistochemistry to suggest
ALK being involved.
CNVs in pediatric melanoma
The MIP assay and WGS revealed genomic instability with
multiple CNVs in each CM (Supplementary Figures S6 and
S11 online). Common regions of alteration in CM were akin to
those reported in adult melanoma (Bastian et al., 1998, 2003)
(Figure 3). Across the entire cohort of 19 melanomas, MIP
analysis found a gain in some portion of chromosome 7q
(79%), 7p (63%), 6p (63%), 1q (58%), and 20q (58%), and a
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Figure 2. Circos plots showing somatic mutation landscape for the five whole genome sequenced samples. Because of the large number of mutations, only
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loss in some portion of chromosome 9p (63%), 5q (58%), 11q
(58%), and 10q (47%) (Supplementary Table S5 online).
Supplementary Figure S12 online shows the prevalence of
gains and losses across the genome for CMs, CNMs, and SMs
separately.
Recurrent oncogenes in pediatric melanoma
Of the 15 CMs, 13 contained an activating BRAF mutation (12
BRAF V600E; 1 dinucleotide BRAF V600K) (Figure 1). Of the
two CMs with wild-type BRAF, one was an acral melanoma
with wild-type KIT (SJMEL001020) and the other was a
nodular melanoma with a missense mutation in PIK3R1
(SJMEL001029) (Figure 1). Integrated analysis showed that
55% of all CMs (Figure 3) and 75% of BRAF-mutant
melanomas had copy gains of BRAF at 7q34. The three
CNMs, in contrast, contained activating NRAS mutations
(pQ61K, pQ61R, and pQ61H) (Figure 1). A tandem duplica-
tion of MITF (cooperating oncogene) was additionally found in
one CNM (SJMEL001005). The five SMs lacked BRAF or NRAS
activating point mutations but rather contained kinase fusions
in a subset, as described above.
Tumor suppressor genes in pediatric melanoma
The PTEN tumor suppressor gene (the negative regulator of the
phosphatidylinositol 3 kinase/AKT pathway) was commonly
disrupted in CM. Gene alterations occurred either by gross
structural changes (deletion or translocations) or at the nucleotide
level (inactivating mutations). Alterations of PTEN, in contrast,
were not found in the three CNMs. Considering limitations of
various tests, the detection of gene alterations varied across
different assays; for example, the FISH and MIP assays revealed
that 54% and 50% of CMs, respectively, have a loss in PTEN at
10q23.3, whereas WGS found an alteration in all 3 CMs ana-
lyzed, truncating mutations in SJMEL001003 and SJMEL001004,
and complex SV in SJMEL001002 (Figures 1 and 2).
Alterations of CDKN2A (the negative regulator of cell cycle
G1 progression) were common in all subtypes of pediatric
melanoma. Although by immunohistochemistry, 66% of CMs
demonstrated complete loss of CDKN2A (p16INK4a) protein,
the detection of gene alteration was variable by different
assays. For example, by the MIP assay, 45% of CMs had
evidence of a copy loss at the locus of CDKN2A (Figure 3),
and by FISH, 50% had evidence of CDKN2A gene deletion
(mono- or biallelic) (Figure 1 and Supplementary Figure S7
online). Loss of protein without gross gene alterations suggests
that the gene might be altered at the nucleotide sequence level
(Jonsson et al., 2010). In fact, WGS revealed homozygous
CDKN2A microdeletions in SJMEL001004 and putative loss of
function SNV in SJMEL001005, whereas FISH in both had
shown no alterations.
TP53 mutations were detected in 2 of 18 WGS/WES
samples; a germline TP53 missense mutation (R213Q) in a
SM (SJMEL001033) and a somatic UV signature TP53 mis-
sense mutation (P278S) in a CM (SJMEL001027) (see details in
Supplementary Materials online).
TERT promoter (TERT-p) is frequently mutated in pediatric CM
The 23 melanomas were analyzed for SNVs in the TERT-p
sequence (Horn et al., 2013; Huang et al., 2013). Of the 15
CMs, 11 tumors had 1 of the 2 known SNVs in mutually
exclusive groups (6 SNV 228; 5 SNV 250), 1 tumor had a 242/
243 dinucleotide variant, and 2 tumors were marked as
indeterminate because of poor sequence quality. Excluding
the 2 indeterminate samples, 92% (12 of 13) of CMs had an
SNV 228 or an SNV 250 or the 242/243 variant mutation in
the TERT-p region. The only CM with wild-type TERT-p was
an acral melanoma (Figure 1). Two CMs contained CC-4TT
mutations: one was the previously described dinucleotide
variant (228/229) and the other was a CC–4TT dinucleotide
variant (242/243) that generated an ETS1 binding site immedi-
ately upstream of the TERT transcription initiation site, similar to
the previously described variant (Horn et al., 2013; Huang et al.,
2013). Remarkably, only the one SM with hematogenous spread
(SJMEL001030), of the total 5 SMs, contained a TERT-p mutation
(SNV 228). On the other hand, none of the three CNMs carried
such mutations (Figure 1).
Germline mutational analysis of melanoma susceptibility genes
Germline DNA screening for mutations in the high-penetrance
melanoma susceptibility genes, CDKN2A and CDK4 (Ward
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Figure 3. Comparing the prevalence of copy number variations (CNVs) across the entire chromosomes between adult and pediatric conventional melanoma.
(a) The frequency of CNVs in 95 nonacral adult cutaneous melanomas using the single-nucleotide polymorphism (SNP) array data from the study by Hodis et al.
(2012) and (b) the frequency of CNVs in 11 pediatric conventional melanomas in our study. The 7q34 locus harboring BRAF was a common region of gain,
whereas 9p21 and 10q23.3, spanning CDKN2A and PTEN, were common regions of loss in both adult and pediatric melanomas.
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et al., 2012), and for a panel of DNA repair genes (Lange et al.,
2011) was negative for a carrier in this cohort. However, 67% (8
of 12) of CMs (excluding the one acral subtype) and 67% (2 of 3)
of SMs carried 1 or 2 of the 4 most common germline MC1R
variants (V60L, V92M, R151C, and R160W). None of the
patients with CNM harbored a germline MC1R variant (Figure 1).
DISCUSSION
To our knowledge, this study is the most comprehensive
genomic analysis of pediatric melanoma reported to date.
Using a combination of sequencing platforms, we found
unique genomic features for the three subtypes of pediatric
melanoma evaluated in this study. Our data showed that
pediatric CM contained a high burden of somatic SNV, far
greater than any other pediatric tumor sequenced in the
Pediatric Cancer Genome Project to date (Supplementary
Figure S9 online). Although compelling epidemiological evi-
dence suggests that UV exposure in early childhood causes
melanoma later in life, the genotoxic effect of UV light has not
been previously explored at the genomic level in pediatric
melanoma. Our study revealed that the vast majority of SNVs
in pediatric CM are C–4T/G–4A transitions, reflective of UV-
induced DNA damage. In addition, with the exception of the
one acral melanoma, all CMs contained a TERT-p C–4T
mutation, providing a molecular basis for the contribution of
UV light in the pathogenesis of the disease in this young
population. These mutations are pathogenically relevant and
have been shown to increase the transcriptional activity of
TERT and to confer oncogenic advantage by enabling mela-
nocytes to sustain their telomere length and become immor-
talized (Horn et al., 2013; Huang et al., 2013).
Our study revealed that 87% of CMs have an activating
BRAF V600 mutation and commonly an alteration in PTEN. In
contrast, CNMs were characterized by NRAS Q61 mutations
and no detectable defect in PTEN. The varied frequency in
PTEN aberration between NRAS- and BRAF-driven melano-
mas reflects their difference in activating intracellular signaling
pathways. NRAS activates both the mitogen-activated protein
kinase and phosphatidylinositol 3 kinase/AKT pathways,
whereas BRAF solely stimulates the mitogen-activated protein
kinase pathway and requires cooperating genetic modifiers,
such as loss of PTEN, to facilitate activation of the phospha-
tidylinositol 3 kinase/AKT pathway (Tsao et al., 2004).
Although all NRAS-mutant melanomas in our series arose
within a congenital nevus, a distinct histopathological subtype
has not been linked to this melanoma genotype in adults
(Curtin et al., 2005; Broekaert et al., 2010). Larger studies are
needed to determine whether or not NRAS-mutant melanomas
in the pediatric population are exclusive to those arising in
association with congenital nevi. Moreover, the oncogenic
role of UV light in CNM will have to be further explored.
Although one CNM (SJMEL001001), a multiply recurrent scalp
melanoma in an infant (Supplementary Figure S1 online),
contained a high burden of UV-signature mutations, the role
of UV radiation in the genesis or progression of melanoma in
this case must be viewed with caution. Malignant melanocytes
are prone to acquire additional UV-induced passenger muta-
tions without contributing to tumor initiation. Regrettably, the
primary diagnostic material was not available to explore the
genomic DNA of this tumor in its earlier phase of develop-
ment. Notably, neither this nor any other patient with CNM in
our series carried germline DNA mismatch repair genes or
MC1R variants (see below). Importantly, none of them carried
a UV-signature TERT-p mutation, suggesting that these tumors
are under a different set of genetic constraints to maintain their
telomere integrity relative to the other subtypes of melanomas.
The clinical and genomic data together suggest that CNM is a
biologically distinct melanoma subtype (Kinsler et al., 2013;
Krengel et al., 2006).
A subset of SMs in our cohort had kinase fusions, consistent
with the oncogenic mechanism recently described in spitzoid
tumors (Botton et al., 2013; Wiesner et al., 2014). SMs and
atypical Spitz tumors belong to a histologic spectrum of
melanocytic tumors with a morphologic resemblance to
Spitz nevus, affecting more commonly younger individuals.
Despite frequent regional nodal involvement, hematogenous
metastasis is rare in these tumors, particularly in children
(o10 years of age). Disease dissemination, however, can
occur on rare occasions but cannot be predicted with certainty
using morphological parameters (Barnhill et al., 1995;
Paradela et al., 2009). The homozygous CDKN2A (9p21)
deletion, recently suggested as a marker of high-risk spitzoid
melanocytic tumors, was not a reliable predictor for extra-
nodal spread in our cohort (Gerami et al., 2013). For example,
two SMs in our study had biallelic loss of CDKN2A, but
neither one developed extranodal metastasis; in contrast, the
metastatic lung nodule in the one disseminating SM retained
both of its CDKN2A alleles (Supplementary Figure S8 online).
Although the most commonly altered gene in melanoma
(Curtin et al., 2005), CDKN2A is retained in a subset
(Bartkova et al., 1996), as demonstrated at the gene and
protein levels in 13% of CMs in our study that overtly
expressed p16 protein (Figure 1). A marker to more accurately
predict the prognosis is desperately needed to assist in the
decision-making process in the management of these lesions.
The one disseminating SM in our study contained a TERT-p
mutation that was identical to the variant seen in CM, whereas
no other SM carried these mutations, suggesting that a
common mechanism of telomere maintenance may be impli-
cated in SM with extranodal metastatic potential and CM. The
prognostic relevance of TERT-p mutations as a potential marker
of aggressive behavior in spitzoid lesions will have to be further
explored in larger cohorts with long-term follow-up data.
Seeking to explain an early onset of melanoma, we
searched potential environmental and genetic predisposing
factors in our patient cohort. A history of excessive sun
exposure or blistering sunburn could not be fully explored in
the historical cases in our cohort, but environmental factors
were considered to be a contributor in the development of CM
in two teenagers engaged in habitual indoor tanning practices.
None of our patients carried the known melanoma suscept-
ibility genes CDKN2A or CDK4, but 67% of those with CM
and SM carried 1 or 2 germline MC1R variants (Figure 1).
MC1R is a highly polymorphic gene in Caucasians, and its
variants are associated with certain phenotypic traits, such as
red hair and fair skin, and an increased susceptibility to
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melanoma (Landi et al., 2006; Raimondi et al., 2008; Ward
et al., 2012). The discovery of other potential germline
polymorphisms implicated in melanoma predisposition in
young people needs to be explored through large-scale
correlative studies.
In summary, our study has demonstrated that CM in
younger patients has many genomic similarities to adult
melanoma, including an enrichment of UV-induced muta-
tions, a high prevalence of UV-signature TERT-p mutations,
and involvement of similar oncogenes and tumor suppressor
genes. The controversies surrounding the diagnosis and prog-
nosis of childhood and adolescent melanoma have led to the
almost uniform exclusion of these patients to date from
promising trials offered for adults, a strategy that has hampered
research efforts and access to treatments in this population.
Collectively, the data from our study suggest that therapeutic
targets for genotype-specific melanoma in adults might be
applicable to pediatric patients. Moreover, our study has
revealed molecular evidence for the contribution of UV light
in pediatric melanoma development. Fighting melanoma
should start with prevention, public awareness, and changing
the attitude toward sun exposure by acquiring a habit of sun
protection starting in early life.
MATERIALS AND METHODS
Institutional approval of experiments was obtained. Written,
informed patient consent was waived because the research
involved no more than minimal risk to the subjects. The human
investigations were performed after approval by the local institutional
review board.
Study population
CM occurred in 15 Caucasian patients aged 11–20 years
(median, 16), with the histologic subtypes of nodular (7), superficial
spreading (5), acral (1), and unknown primary (2) (Figure 1). At last
follow-up (mean, 30 months), 10 patients had died of disease,
3 were alive with disease, and 2 had no evidence of disease. CNM
affected 3 children r5 years of age who died of disease within an
average of 22 months. SM occurred in 5 patients (3 children, 1
adolescent, and 1 borderline age), of whom 1 died of disease and 4
were alive with no evidence of disease at last follow-up (mean, 32
months) (Figure 1 and Supplementary Table S1 online).
Whole genome sequencing
DNA was isolated from seven fresh frozen tumor samples and
matched blood from five patients (Figure 1). Sequencing was
conducted on a HiSeq 2000 (Illumina, San Diego, CA) using the
paired end 2 100 cycle protocol, as previously described (Zhang
et al., 2012). Validation of variants identified in WGS data was
performed as described previously (Chen et al., 2014).
Whole exome sequencing
DNA was isolated from 14 paired FFPE tumor (11 CMs and 3 SMs)
and normal tissue/blood samples. WES was completed in 10 samples
(8 CMs and 2 SMs) with 87.4 and 90.3% of exonic bases covered at
least 20-fold in the tumor and matched normal germline DNA (details
in Supplementary Materials online; Supplementary Figure S2 and S10
online).
RNA sequencing
RNA was isolated from frozen tumors (5 CMs and 1 CNM) and FFPE
tumors (3 SMs) (details in Supplementary Materials online). The sequen-
cing data were generated as previously described (Parker et al., 2014).
Affymetrix OncoScan MIP assay
Genomic DNA was extracted from FFPE sections of 19 melanomas
(Figure 1), guided by the corresponding hematoxylin and
eosin–stained slides, to attain 480% tumor purity. DNA was
extracted using the QIAamp DNA FFPE tissue kit (Qiagen Sciences,
Germantown, MD) according to the manufacturer’s instruction
(details in Supplementary Materials online). A minimum quantity of
200 ng of genomic DNA was used as input per Affymetrix OncoScan
guidelines (Affymetrix, Santa Clara, CA).
Mutation analysis of BRAF and NRAS
Mutational hotspots for BRAF (exon 15) and NRAS (exons 1 and 2)
were screened in genomic DNA of 23 melanomas. PCRs were
performed using GoTaq Long PCR Master Mix (Promega, Madison,
WI). Direct sequencing of PCR products was performed using
BigDye version 3.1 and a 3730XL DNA analyzer (Applied Biosys-
tems, Foster City, CA). Results were screened using CLC Main
Workbench sequence analysis software version 6.0.2 (CLC bio,
Cambridge, MA).
Mutation analysis of TERT-p
A portion of the TERT-p (HG19 coordinates, chr5: 1295151-1295347)
was amplified in 23 melanomas by PCR. Briefly, 20–50 ng of sample
DNA was added to a 25ml reaction containing amplitaq gold
360 master mix (Applied Biosystems) with 400 nM each of amplifica-
tion primers (details in Supplementary Materials online). The sequen-
cing and analysis were performed as described in the previous
section.
Data analysis and statistical methods
See Supplementary Materials online.
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